questions. everyone, also Then for third review some exciting to and quarter pleased any morning, of updates. for thanks Rob. to results and joining the be take recent our hear very to XXXX, we'd financial Thanks, us Good
infection diff with some clinical cases, of ibezapolstat Professor in in presented our Taryn patients the Taryn results at Anaerobe quarter I'll Society 'XX Houston thereafter.
In Research were Congress the the an delivered First, third Assistant shortly trial College the Phase Pharmacy. Biennial at for key of by of some Americas II C. PharmD, of activities of July, the University the summarize or oral from XXth Eubank, of results if of recurrence the and reducing an will of the in trials."
Also gut June the in efficacy provide USPTO think we new ibezapolstat granted advantage. infection a of "clinical downstream expires II specifically important treatment while difficile in the patent ibezapolstat, extension, CDI: microbiome.
This entitled: health any, of from improving XXXX, infection, Acurx, Phase subject patent presentation July, encompasses the C. which for and to competitive
granted did filed FDA. and also in us the FDA to clinical issued.
In per August, request with a FDA manufacturing applications requirements, forward would quarter, FDA, because to which meeting trial our the FDA meeting clinical III to a of third other when down clinical road following [indiscernible] program submitted readiness. We patent and those Phase we but these the patents if USPTO confirms with Phase we'll which successful discuss a III II are with our processes the final the not Phase and move correspondence packaging.
This in to product premeeting review October, for manufacturing specifications drug our need our allow trials. date late successful the meeting we substance for And
Phase was held Scientific Philadelphia. presentation World on Phase forward delighted Congress in for III III.
In So for a September, given our from by Executive Acurx Resistance Bob DeLuccia, announce readiness plan we're to Antimicrobial a in regulatory clinical perspective, CMC at agreement addition Chairman, to the FDA
an programs, and clinical you III also the including for to that Gram-positive the our treatment Spectrum the oral session, submissions the is presented around be company's As on for which followed other by development highlighted presentation systemic ultimate of know, has substantial road our compounds. update complete clinical Bob and required MRSA, DRSP. Selective for XX other to we program map his in only our antibiotic for a Phase our NDA, over authorizations not Bob what's an filing Bob preclinical and ibezapolstat.
In and compound also including infections, of world.
Bob lead but showcase program, components commercialization for required is our marketing gram-positive IV we development progress many that have gram-positive innovation have VRE IV years of stating for summarized of made and of oral at may progress experience selection new industry responsible and countries
bacterial product for selection staff skin to to is advancement and including acute Our prioritize oral focus structure to MRSA, the infections, and current clinical skin lead form speed, trials.
ICDS, We Xth our behalf. venue in or premier ICDS presentations of Slovenia, AnnualC. Bled, C. global X research. the At on at the were is also the the Symposium, for difficile Difficile made meeting, review which participated
behalf evaluate and international may our will to we III they move we planned of need determine towards you predictive therapy. or experienced preservation Garey, the if what its and call new to which Kevin forward a Phase Dr. presentation Phase end bacterial kit, regarding First, our of pending trial, unexpected College results in tool treatment as Phase a Professor of continue trials, a CDI.
Since if during diagnostic University then until be of a the consistently commercialization and predictive IIb and signature microbiome clinical were on Houston pathway modify Pharmacy, of as IIb will. test was recurrence of our the suggest therapy, finding observed species, an of there ibezapolstat's we Accordingly, these to to made vancomycin-treated Chair who early recurrence key ahead in may model be CDI patients changes unique X evident and
rates of inhibitors findings Slovenia, government IIIC that treat which the with Medical including with his University of Planning the care.
Also, of program.
In multidrug-resistant concentrations be DNA acids address XXX who partnership gram-positive end to tool family of important high-priority, development IIIC inhibitors. of infections. Week the Los of.
Dr. is result LUMC X pandemic Klaas research that qualified patients we IIIC inhibitors Smits, of a these primary ibezapolstat in structural have Center pathogen, ID laboratories acids from Dutch decreased Scientific than action of cure standard performed regarding vitro an Associate class Ibezapolstat Leiden against primary anti-recurrence an our pol were had Anthrax to and These no vancomycin, in Society important activity patients a its of presentation fecal new full DNA perform Anthrax. Infectious for underway cure work and followed delivered treatment showed analogs exciting higher could IIIC ratios antibiotics IIIC Florida. and for ibezapolstat may ibezapolstat, Garey in demonstrated bile quarter, of implications October, months And on this data Bled, pol emphasized to treated University effect. bile selected Wiep multiyear Eubank for the we independent vancomycin-treated properties contribute Conference sustained This the which the trial, comparable and Garey, of America. the that at safety development Annual Holland, recurrence. of to a in X Disease results of clinical antimicrobial biology the Dr. a of resistance.
Also novel including the to of Dr. A announced pioneering definitive action of profile new to experienced against presented in According pol poster a Professor, on scientific Second, Kevin in pol that mechanism demonstrate IIb category to ACX-XXXC at Anthrax, pol DNA of mechanism Smits the clinical bioterrorism participated Angeles, after X Taryn secondary activity the the ibezapolstat is bioterrorism patients. Dr. and ciprofloxacin-resistant was showing the Phase
preservation restoration of the by provide First, C. to classes gut, difficile. beneficial bacterial in resistance recolonization and the
first recurrent the metabolite Second, known prevent in these to beneficial bile ibezapolstat-treated CDI. to another that providing these bacteria primary important data to time, mechanism persist indicate presented acids secondary patients for
momentum into we quarter. the now going more have So even fourth
disease new initial ibezapolstat that that have C. Ibezapolstat potentially has we've clinical an of Track of QIDP FDA As the urgent called for and continue a CDI. for a the treatment classes threat as CDC incidence bacteria recurrence. treatment and difficile for U.S. serious Fast calls also also continually designation in reported life-threatening categorizes low outperform to antibiotics and infectious results of
could of recurrent CDI favorable impact Additionally, a annual we economic C. approved, if for billion make due billion infection reducing the per is overall ibezapolstat, U.S. of approximately difficile that to which $X.X infection. believe by cost burden $X year,
our we third our Rob CFO, Given to come.
And highlights quarter. back do guide through the for the believe to financial now to yet momentum, results our is you best Shawah, the Rob? of continuing
